MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

Kodu・Aktsiate loetelu・Simulations Plus Inc

Simulations Plus Inc

Avatud

SektorTervishoid

14.25 -2.4

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.89

Max

14.76

Põhinäitajad
By Trading Economics
Sissetulek	3.9M 4.5M
Müük	5.9M 24M
Aktsiakasum	0.35
Dividenditootlus	0.48
Kasumimarginaal	18.669
Töötajad	212
EBITDA	4.9M 7.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+66.43% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.48% 2.38%
Järgmine tulemuste avaldamine	13. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	11M 262M
Eelmine avamishind	16.65
Eelmine sulgemishind	14.25

Uudiste sentiment

By Acuity

50%

162 / 348 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. apr 2026, 23:26 UTC

Kuumad aktsiad

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16. apr 2026, 20:41 UTC

Suurimad hinnamuutused turgudel

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16. apr 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16. apr 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16. apr 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16. apr 2026, 22:08 UTC

Tulu

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16. apr 2026, 20:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Tulu

Health Care Roundup: Market Talk

16. apr 2026, 20:49 UTC

Tulu

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16. apr 2026, 20:43 UTC

Tulu

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. apr 2026, 20:40 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

16. apr 2026, 20:40 UTC

Market Talk

Tulu

Netflix Says Engagement Quality Hits New High -- Market Talk

16. apr 2026, 20:30 UTC

Kuumad aktsiad

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16. apr 2026, 20:25 UTC

Tulu

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. apr 2026, 20:23 UTC

Tulu

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16. apr 2026, 20:19 UTC

Tulu

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16. apr 2026, 20:17 UTC

Tulu

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16. apr 2026, 20:17 UTC

Tulu

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

66.43% tõus

12 kuu keskmine prognoos

Keskmine 23.5 USD 66.43%

Kõrge 31 USD

Madal 16 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Simulations Plus Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

162 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.